Company Grows Leading Patent Position in Patient-Specific Implants and Patient-Specific Instrumentation

Burlington, Mass. – February 6, 2012 – Conformis, Inc. today announced it has completed its most productive period to date in the development of its intellectual property with the addition of 22 issued patents to its portfolio since January 2011. The core of its portfolio covers patient-specific implants and patient-specific instrumentation systems spanning applications in knee, hip, shoulder, small joint, and spine. With these recent patent awards, Conformis now owns or exclusively licenses more than 50 issued patents.

The company, a leader in the area of patient-specific implants and instrumentation systems, already possesses a substantial intellectual property portfolio consisting of more than 300 patents and patent applications. The IP portfolio covers a broad range of related areas including imaging software, image processing, implant design, surgical techniques, instrumentation, and manufacturing. Over the past year, Conformis has received a number of patents specifically in the area of patient-specific implants and instrumentation systems. A partial list is provided below.

“We are very proud of the progress we have made over the past year and with the tremendous value that Conformis’s intellectual property, both its developed technology and the corresponding patent rights, has added to the company,” said Philipp Lang, MD, MBA, CEO and Chairman of the Board of Conformis. “Our patent portfolio provides Conformis with great opportunities to develop its technology in the market, and we will continue to pursue additional intellectual property rights and further develop our patent portfolio as we move forward.”

Since its founding in 2004, Conformis, the fastest growing orthopedic implant company, has built and brought to market the only full line of patient-specific implants and instruments for the treatment of knee osteoarthritis, a $7 billion global market. In 2010, the company launched their second generation personalized partial knee solutions, the iUni^® G2 and iDuo^® G2. In 2011, Conformis received 510(k) clearance from the United States Food and Drug Administration to market the iTotal^® CR Knee Replacement System, the first and only patient-specific total knee implant on the market.

For more information on Conformis visit www.conformis.com.

About Conformis, Inc. 
Conformis, Inc. is a privately-held company that develops and commercializes medical devices for osteoarthritis treatment and joint damage. Its proprietary intellectual property includes more than 300 patents and patent applications in the areas of imaging software, image processing, implant design, surgical techniques, instrumentation, and manufacturing, spanning knee, hip, shoulder, spine, and small joints. Conformis knee implants and instrumentation are designed to address all stages of osteoarthritis, the most common reason for knee replacement surgery. All devices have been cleared by the US Food and Drug Administration for marketing in the US. In 2009, Conformis was named a winner of the Medical Design Excellence Awards, the premier recognition for contributions and advances in the design of medical products, for its iUni and iDuo resurfacing implants. In 2011, Conformis received the American Technology Award for innovation with its iTotal CR product. Follow Conformis on Twitter at @ Conformis and become a fan on Facebook at www.facebook.com/Conformis.